Jacob C. Kimmel Jacob Kimmel is the co-founder and CEO of NewLimit, a biotechnology company developing epigenetic reprogramming medicines. Previously, he led research at Calico focused on engineering cell identity and reprogramming cell age. He holds a Ph.D. from the University of California, San Francisco.
Jacob C. Kimmel Jacob Kimmel is the co-founder and CEO of NewLimit, a biotechnology company developing epigenetic reprogramming medicines. Previously, he led research at Calico focused on engineering cell identity and reprogramming cell age. He holds a Ph.D. from the University of California, San Francisco.